These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20006499)

  • 1. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
    Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ
    Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs.
    Young RJ; Adams C; Blows M; Brown D; Burns-Kurtis CL; Chan C; Chaudry L; Convery MA; Davies DE; Exall AM; Foster G; Harling JD; Hortense E; Irvine S; Irving WR; Jackson S; Kleanthous S; Pateman AJ; Patikis AN; Roethka TJ; Senger S; Stelman GJ; Toomey JR; West RI; Whittaker C; Zhou P; Watson NS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1582-7. PubMed ID: 21349710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Convery MA; Diallo H; Hortense E; Irving WR; Kelly HA; King NP; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2008 Jan; 18(1):28-33. PubMed ID: 18053714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.
    Watson NS; Brown D; Campbell M; Chan C; Chaudry L; Convery MA; Fenwick R; Hamblin JN; Haslam C; Kelly HA; King NP; Kurtis CL; Leach AR; Manchee GR; Mason AM; Mitchell C; Patel C; Patel VK; Senger S; Shah GP; Weston HE; Whitworth C; Young RJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3784-8. PubMed ID: 16697194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
    J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.
    de Candia M; Fiorella F; Lopopolo G; Carotti A; Romano MR; Lograno MD; Martel S; Carrupt PA; Belviso BD; Caliandro R; Altomare C
    J Med Chem; 2013 Nov; 56(21):8696-711. PubMed ID: 24102612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective synthesis and glycosidase inhibitory activity of 3,4-dihydroxy-pyrrolidin-2-one, 3,4-dihydroxy-piperidin-2-one and 1,2-dihydroxy-pyrrolizidin-3-one.
    Coutrot P; Claudel S; Didierjean C; Grison C
    Bioorg Med Chem Lett; 2006 Jan; 16(2):417-20. PubMed ID: 16271473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties.
    Yoshikawa K; Kobayashi S; Nakamoto Y; Haginoya N; Komoriya S; Yoshino T; Nagata T; Mochizuki A; Watanabe K; Suzuki M; Kanno H; Ohta T
    Bioorg Med Chem; 2009 Dec; 17(24):8221-33. PubMed ID: 19900814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.
    Zbinden KG; Obst-Sander U; Hilpert K; Kühne H; Banner DW; Böhm HJ; Stahl M; Ackermann J; Alig L; Weber L; Wessel HP; Riederer MA; Tschopp TB; Lavé T
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5344-52. PubMed ID: 16213138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
    Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.